Study on the influence of mCRP on the curative effect of herceptin on breast cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-09000620

Enrollment

Unknown

Registered

2010-12-22

Start date

2010-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Group A:Expression level of CD55,CD59 and CD46 in tissues

Group B:Expression level of CD55,CD59 and CD46 in tissues

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Breast cancer with her-2 over expression and treated with herceptin.

Exclusion criteria

Exclusion criteria: Breast cancer without her-2 over expressin and without treatment with herceptin.

Design outcomes

Primary

Measure	Time frame
Expression level of CD55,CD59 and CD46 in tissues;	—

Countries

China

Contacts

Public ContactYanping Wang

huyongwyp@vip.sina.com+86 18980601827

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026